Wednesday, June 10, 2026

pharma · Amyotrophic Lateral Sclerosis · Acute Myeloid Leukemia

AB Science

AB Science patent portfolio — 25 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

PARIS, FR HQ
20 Employees
EMA registrant Type
Company details
Status
Public
HQ
PARIS, FR
Employees
20
Programs
6
Drugs
11
Patents
25
Intelligence · Patents

AB Science patents

25 pharmaceutical patents indexed for AB Science. 0 expire within 24 months.

AB Science has 25 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Patent portfolio

  1. WO 2025027051

    INHIBITEURS DE SPHINGOSINE-1-PHOSPHATE LYASE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES

    Expires Wed Feb 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. WO 2024175803

    COMPOSÉS POUR LE TRAITEMENT DE MALADIES MYÉLOÏDES AVEC DES ANOMALIES CHROMOSOMIQUES

    Expires Wed Aug 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. WO 2024146923

    INHIBITEURS DE POLYMÉRISATION DE TUBULINE

    Expires Wed Jul 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. CN 117980330

    Homodimeric peptides and antibodies comprising same

    Expires Thu Apr 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. CA 3217490

    MASITINIB POUR LE TRAITEMENT DU CANCER DE LA PROSTATE RESISTANT A LA CASTRATION

    Expires Wed Nov 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. WO 2022234069

    NOUVEAUX DÉRIVÉS DE 2-AMINOOXAZOLE ET LEUR UTILISATION POUR LE TRAITEMENT DE MALADIES INFECTIEUSES

    Expires Wed Nov 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. CA 3201259

    MASITINIB POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER

    Expires Wed Jun 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. CA 3174748

    UTILISATION DE MASITINIB POUR LE TRAITEMENT DE LA MALADIE A CORONAVIRUS 2019 (COVID-19)

    Expires Wed Oct 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. CA 3168610

    MASITINIB POUR LE TRAITEMENT D'UNE SOUS-POPULATION DE PATIENTS SOUFFRANT DE SCLEROSE EN PLAQUES

    Expires Wed Aug 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. EP 3831384

    VERWENDUNG VON MASITINIB ZUR BEHANDLUNG VON EOSINOPHILEM ASTHMA

    Expires Tue Jun 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. WO 2021099616

    MASITINIB POUR LE TRAITEMENT DE LA DRÉPANOCYTOSE

    Expires Wed May 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. CA 3018635

    UTILISATION DE MASITINIB POUR LE TRAITEMENT D'UNE SOUS-POPULATION DE PATIENTS ATTEINTS DE SCLEROSE LATERALE AMYOTROPHIQUE

    Expires Wed Sep 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 2017119760

    USE OF MASITINIB FOR THE TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY

    Expires Wed Apr 29 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. WO 2017072335

    UTILISATION DE MASITINIB ET D'AUTRES INHIBITEURS DE MASTOCYTE POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON

    Expires Wed Apr 29 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. CA 3000894

    TRAITEMENT DE LA MASTOCYTOSE SYSTEMIQUE GRAVE PAR LE MASITINIB

    Expires Wed Apr 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. EP 3144307

    NEUE OXAZOL DERIVATEN ALS SYK KINASEHEMMER

    Expires Tue Mar 17 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 2017020867

    USE OF MASITINIB FOR THE TREATMENT OF CROHN'S DISEASE

    Expires Wed Jan 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  18. EP 3053920

    VERBINDUNGEN MIT ANTITUMORAKTIVITÄT

    Expires Tue Aug 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  19. US 2016175302

    MASITINIB FOR TREATING GASTRIC CANCER

    Expires Wed Jun 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  20. WO 2016096933

    MASITINIB COMBINÉ À UTILISER DANS LE TRAITEMENT DU CANCER DU SEIN

    Expires Wed Jun 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  21. WO 2016085391

    DÉRIVÉS DE BIS (SULFONAMIDE) ETLEUR UTILISATION COMME INHIBITEURS DE MPGES

    Expires Wed May 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  22. WO 2016085392

    DÉRIVÉS DE BIS (SULFONAMIDE) ET LEUR UTILISATION COMME INHIBITEURS DE MPGES

    Expires Wed May 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  23. US 2016128999

    MASITINIB FOR TREATING HEPATIC CANCER

    Expires Wed May 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  24. WO 2016071511

    TRAITEMENT DU SYNDROME D'ACTIVATION MASTOCYTAIRE (SAMA) AVEC LE MASINITIB

    Expires Wed May 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  25. US 2016089368

    TREATMENT OF MASTOCYTOSIS WITH MASITINIB

    Expires Wed Mar 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does AB Science have?

25 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do AB Science patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.